發(fā)布時間：2018-08-20 17:36

【摘要】：目的:系統(tǒng)評價新型GLP-1受體激動劑利司魯肽治療2型糖尿病的療效與安全性。方法:電子檢索中英文數據庫中有關利司魯肽治療2型糖尿病的隨機臨床試驗(RCT),時限至2016年5月;2位研究者獨立評閱文獻,并篩選及予以質量評價;采用RevMan 5.0軟件對各效應指標進行Meta分析。結果:納入7篇RCT,文獻質量評價均屬低偏倚風險,2型糖尿病患者共計2 089例,其中試驗組(利司魯肽治療)1 128例,對照組(安慰劑)961例,Meta分析結果顯示,于治療周期末,2組HbA1c水平、HbA1c達標率(≤6.5%)有統(tǒng)計學差異(P0.05),FPG水平變化無統(tǒng)計學差異(P0.05),惡心、嘔吐、胃腸功能紊亂、低血糖反應及因不良事件(AE)退出治療的發(fā)生率有統(tǒng)計學差異(P0.05),腹瀉、頭痛、頭暈、鼻咽炎及SAE發(fā)生率無統(tǒng)計學差異(P0.05)。結論:利司魯肽對2型糖尿病患者血糖水平有較好控制作用,但其不良反應發(fā)生率仍有較大差異,尚需更多大樣本、多中心隨機臨床試驗予以證實。
[Abstract]:Objective: to evaluate the efficacy and safety of a novel GLP-1 receptor agonist, riselutin, in the treatment of type 2 diabetes mellitus. Methods: the (RCT), time limit of the randomized clinical trial of Lisrop for type 2 diabetes mellitus was searched electronically in Chinese and English database, and two researchers independently reviewed the literature until May 2016, and selected and evaluated the quality of the literature. RevMan 5.0 software was used to analyze each effect index by Meta. Results: a total of 2 089 patients with type 2 diabetes mellitus with low bias risk were included in 7 RCTs, including 1 128 patients in the trial group (treated with risurutin) and 961 patients in the control group (placebo). At the end of the treatment cycle, there was no significant difference in the HbA1c level (鈮，

本文編號：2194447